Die 1000% Chance noch dieses Jahr....
Seite 4 von 107 Neuester Beitrag: 25.04.21 13:13 | ||||
Eröffnet am: | 15.02.06 19:16 | von: Happydepot | Anzahl Beiträge: | 3.653 |
Neuester Beitrag: | 25.04.21 13:13 | von: Ursulajkdba | Leser gesamt: | 201.838 |
Forum: | Hot-Stocks | Leser heute: | 186 | |
Bewertet mit: | ||||
Seite: < 1 | 2 | 3 | | 5 | 6 | 7 | 8 | 9 | ... 107 > |
Bin ja nicht investier bei Genta
aber abwarten bei dem Kurs bzw der noch fallen wird ...
Für mich istdie Aktie im Moment eh nur ein Zock wert
Für Long Invest .. Kennst ja den chart
Wer weiss, aber eins steht fest: Tesetaxel ist im Erfolgsfalle mehrere Milliarden
$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
wert. Aber nur dann. Und wenn man wiederum berücksichtigt, dass man selbst bei der jetzigen Anzahl noch rechnen kann, dass im Erfolgsfalle und eventuell schon bei guten News der Kurs sicherlich bei $0,10 oder höher stehen könnte, dann wäre das ein gutes Geschäft. Genta mit Tesetaxel ist meiner Meinung nach selbst im Entwicklungsstadium noch zwischen 50 und 100 Millionen wert.
Niemand würde da frisch einsteigen, wenn der Laden dicht wäre.
Perf. seit Threadbeginn: -100,00%
§
post #76 lesen
Genta Incorporated is a biopharmaceutical company focused on the identification, development and commercialization of drugs for the treatment of people with cancer. We have built a broad portfolio of proprietary products in various stages of clinical development. Genta is committed to developing innovative products to better the lives of people with cancer.
Genta stock is currently worth $6.90 per share, one of my greatest pick on the stock market is Pfizer and the main reason is because pharmaceutical companies are always advancing and advancing fast. At CIG Investments Genta is a major stock and all of our brokers are suggesting to bring their clients in on Genta Incorporated.
Genta has products already on the market one of their products on the market is called Ganite and has been a great success with patients. Ganite is FDA approved. Genta is releasing three other products. Two have already passed preclinical trials. Tesetaxel which has just finished phase two with Genta's research team, Oral Gallium which is halfway through Genta's phase 1 trial with their research team, and Daltredaxx which is about to begin preclinical trials with Genta's research team in May. Products released by Genta are all to be FDA approved, Ganite has been approved by the FDA.
When Genta releases a new product on the market their stock price soars and investors retrieve great profits. Back in September 2011 Genta's stock was worth approximately $2.80 but within three to six months the stock soared by $4.10. Stock analysts at CIG Investments are saying that Genta Incorporated is the next Pfizer of the pharmaceutical business. This stock will continue to soar and will inflate in value as a licensed stock broker I highly suggest to buy now! before the stock rises in value. Buy Genta Incorporated stock now and sell it off within six months when it will be worth $10 or more.
Genta also stated that in May 2012 they are in talks with Pfizer to create a new partnership so Pfizer may help Genta with their preclinical trials, manufacturing, and distribution on Daltredaxx.
For more information about Genta Incorporated stock you may call CIG Investments at (514) 558-4838 or email us at churchill@representative.com for more info about this incredible stock. If you would like more information about Genta Incorporated feel free to visit http://www.genta.com/ follow the link and you may learn more about Genta and its products. Once again call CIG Investments for more information about the Genta stock call us at (514) 558-4838 or email us at churchill@representative.com
wenn es stimmen sollte.....
einen Wert von 6,90$?
Unmöglich!!!
Genta hat für Tesetaxel fast-track status beantragt und wohl auch bekommen. Bei anderen Firmen, die ähnliche Medikamente entwickeln, ist kein fast-track status vergeben worden. An was liegt das wohl?
tote Hose. Meinst du mit pushen bekommst du was bewegt und das noch in Deutschland?